The rapid expansion of the GLP-1 receptor agonist market is driving an unprecedented reallocation of capital across the pharmaceutical industry. Global sales for obesity and diabetes treatments are projected to surpass $100 billion annually by 2030, shifting strategic focus away from traditional therapeutic areas.
Manufacturing Bottlenecks and Biosimilars
Contract development and manufacturing organizations (CDMOs) are operating at maximum fill-finish capacity to meet demand. Pipeline developers are now prioritizing oral formulations and longer-acting monthly injectables to capture market share ahead of patent expirations.